Alzheimer Disease without Neurofibrillary Tangles

Types
Causes
Symptoms
Diagnostic tests
Non-pharmacological treatments
Drug treatments
Dietary molecular supplements
Immunity booster / regenerative / stem-cell” drugs
Surgeries
Prevention tips
When to see a doctor (red flags)
What to eat and what to avoid
FAQs

Alzheimer disease without neurofibrillary tangles” means a situation where a person shows Alzheimer-type amyloid plaques in the brain, but tau neurofibrillary tangles are not found (or are not detected by current tests). In classic Alzheimer’s disease, doctors expect both plaques and tangles. Modern research standards say that true Alzheimer’s disease is biological and needs proof of both amyloid and tau—either at autopsy or with living-person biomarkers (brain scans, spinal fluid, or blood tests). If amyloid is present but tau is not, many experts now call this “Alzheimer’s pathophysiology” or “amyloid-only stage,” not full Alzheimer’s disease. Some people with this pattern may have no symptoms (they are “resilient”), while others may have memory problems due to other causes that look like Alzheimer’s. PMC+2aaic.alz.org+2

Alzheimer’s disease without neurofibrillary tangles means a person has Alzheimer-type changes—especially amyloid-beta build-up (Aβ plaques)—but little or no tau tangles in the brain on today’s tests. In classic Alzheimer’s, doctors usually find both Aβ plaques and tau neurofibrillary tangles. When tangles are missing or very low, the picture is different. Some experts call this “plaque-only” Alzheimer pathology or amyloid-predominant, tangle-negative disease. In modern biomarker language (the A/T/N system), this often looks like A+ (amyloid positive), T− (tau negative), N± (neurodegeneration may or may not be present).

Importantly, a classic pathology paper described “plaque-only Alzheimer disease (POAD)” at autopsy—brains with plaques but no cortical tangles—and compared them with the usual plaque-and-tangle form. This showed that plaque-only brains can occur, though this entity is uncommon and its clinical meaning is debated. PubMed

Researchers also emphasize that tangles correlate best with thinking decline, while plaques alone often do not. That is one reason today’s definitions require both pathologies to diagnose Alzheimer’s biologically. PMC+1

Other names

Plaque-only Alzheimer disease (POAD) – a historical/neuropathology term used in autopsy studies. PubMed
Amyloid-only (A+T–) stage / Alzheimer’s pathophysiology – modern biomarker language meaning amyloid positive, tau negative. aaic.alz.org
Preclinical amyloidosis – amyloid found in people without symptoms; many such people never develop dementia. JAMA Network
Tangle-free dementia (historical) / DLDH (dementia lacking distinctive histology) – older labels for dementia cases where typical signature changes (including tangles) weren’t seen with older techniques; many of these are now reclassified into other disorders. PubMed+1

Types

Asymptomatic amyloid-only brains
People with significant amyloid burden but no symptoms and no tau—sometimes called resilient brains. They may stay cognitively normal for years. JAMA Network+1
Amyloid-only with mild memory symptoms
Individuals with amyloid on PET or at autopsy but tau negative, with mild cognitive complaints; symptoms may reflect other problems (e.g., small strokes, depression, sleep disorders). Modern criteria would not label this “Alzheimer’s disease” unless tau becomes positive. PMC
Plaque-only at autopsy (POAD)
Brains showing abundant plaques and few or no tangles on detailed post-mortem study. The clinical picture during life can be variable. PubMed
Alzheimer-like symptoms from other diseases
Some diseases mimic Alzheimer’s (e.g., LATE—a TDP-43 protein disorder—and some frontotemporal or vascular disorders) and may show no tau tangles of Alzheimer type. PMC

Causes

Early amyloid buildup (amyloidosis) without tau
Amyloid can accumulate years before tau changes or symptoms appear. Some people remain well. PMC+1
Biological definition thresholds
By today’s rules, A+T– is called Alzheimer’s pathophysiology, not Alzheimer’s disease. The “cause” of the tangle-negative pattern is simply that tau has not appeared (yet or ever). aaic.alz.org
Genetic risk for amyloid (APOE-ε4)
APOE-ε4 raises amyloid risk. Some carriers show amyloid positivity while tau remains negative for a time. (APOE-ε4 is a risk gene, not a diagnosis.) PMC
Cerebral amyloid angiopathy (CAA)
Amyloid can deposit mainly in brain vessel walls, causing cognitive issues or microbleeds, without classic Alzheimer tau tangles. PMC
“Resilience” factors
Some people tolerate plaques without decline because of brain reserve or protective biology—an active research area. PMC
Sampling/measurement limits
Tau can be patchy. Limited biopsy, limited autopsy sampling, or early PET/CSF thresholds may miss sparse tangles. BioMed Central
Age-related “amyloid first, tau later” timeline
Biology often shows a sequence: amyloid abnormalities first, tau later. A snapshot can catch the amyloid-only stage. PMC
Comorbid vascular disease
Small vessel disease or microinfarcts can drive symptoms even when tau is absent; amyloid may be incidental. BioMed Central
LATE (limbic-predominant age-related TDP-43 encephalopathy)
A different protein (TDP-43) can cause an Alzheimer-like memory syndrome without Alzheimer-type tangles. PMC+1
Frontotemporal lobar degeneration (FTLD) variants
Some FTLD forms produce dementia without Alzheimer tangles; earlier literature sometimes called them “lacking distinctive histology.” PubMed
Lewy body disease with co-amyloid
Some people have Lewy bodies plus amyloid plaques; tangles may be minimal. Symptoms lean toward attention, visual, and parkinsonism features. BioMed Central
Traumatic brain injury history
Head trauma can alter amyloid processing and cognition without typical tau tangle distribution of Alzheimer’s. BioMed Central
Severe sleep problems
Chronic sleep loss affects amyloid clearance and thinking; tau signatures may remain negative for a time. BioMed Central
Depression or anxiety causing “pseudodementia”
These can mimic Alzheimer-like symptoms, while amyloid may be incidental and tau negative. BioMed Central
Medication effects (anticholinergics, sedatives)
These drugs can impair memory and attention without Alzheimer tangles. BioMed Central
Endocrine/metabolic problems (e.g., thyroid disease, low B12)
Reversible causes of cognitive symptoms; amyloid positivity may be unrelated. BioMed Central
Hearing loss and social isolation
Both raise dementia risk and can mimic Alzheimer’s clinically; tau may be negative. BioMed Central
Chronic inflammation or systemic illness
Inflammation can worsen cognition and interact with amyloid biology without producing tangles. BioMed Central
Normal aging with incidental amyloid
A proportion of older adults have amyloid yet remain cognitively normal for years. JAMA Network
True “plaque-only” neuropathology (POAD)
At autopsy, some brains show plaques without cortical tangles—confirming this pattern exists, though uncommon. PubMed

Symptoms

Note: Symptoms vary widely. In amyloid-only (A+T–), symptoms may be absent or due to another condition. When symptoms occur, they often resemble early Alzheimer-like complaints.

Short-term memory trouble – repeating questions, misplacing items. (Common in many disorders, not specific.) BioMed Central
Word-finding pauses – takes longer to name objects. BioMed Central
Reduced attention and processing speed – harder to multitask. BioMed Central
Planning and organizing problems – bills, schedules, step-by-step tasks become harder. BioMed Central
Spatial confusion – getting turned around in new places. BioMed Central
Judgment changes – riskier choices or difficulty weighing options. BioMed Central
Apathy or low motivation – less initiative. BioMed Central
Mood changes – anxiety, irritability, or depression. BioMed Central
Sleep disruption – insomnia or fragmented sleep, which can worsen thinking. BioMed Central
Navigation trouble while driving – more reliance on GPS. BioMed Central
Complex language difficulty – following long stories or instructions is harder. BioMed Central
Reduced insight – the person may under-report their problems. BioMed Central
Fluctuations in attention – especially if another disease (like Lewy body) is present. BioMed Central
Mild personality change – more withdrawn or disinhibited. BioMed Central
Daily living strain – cooking, finances, or medications need more help. BioMed Central

Diagnostic tests

A) Physical examination (general check-up in the clinic)

Neurological exam
The doctor checks strength, reflexes, balance, coordination, eye movements, and senses. This looks for signs of stroke, Parkinsonism, or neuropathy that could explain symptoms. In amyloid-only patterns, the exam is often normal or shows mild, nonspecific changes. BioMed Central
Vitals and medical review
Blood pressure, heart rhythm, weight loss, sleep pattern, and medication review help find non-Alzheimer causes of cognitive problems (e.g., hypotension, sedatives). BioMed Central
Gait and balance assessment
Abnormal gait can hint at vascular disease or other neurodegenerative conditions, guiding testing beyond Alzheimer biomarkers. BioMed Central
Hearing and vision screens
Treatable sensory loss can mimic or worsen memory and attention problems. BioMed Central

B) Manual/bedside cognitive tests

Mini-Mental State Examination (MMSE)
A quick paper test for orientation, attention, memory, language, and drawing. It gauges severity but does not prove Alzheimer’s. Scores may be normal early on. BioMed Central
Montreal Cognitive Assessment (MoCA)
More sensitive for mild problems in attention, executive function, and memory. Helpful for early detection but not disease-specific. BioMed Central
Clock drawing / Trail Making
Simple tasks that stress planning, attention, and visuospatial skills. Patterns of errors can hint at non-Alzheimer causes too. BioMed Central
Full neuropsychological evaluation
A multi-hour, standardized battery that maps strengths and weaknesses across memory, language, attention, and executive function—useful for differential diagnosis when biomarkers disagree. BioMed Central

C) Lab and pathological tests

Basic blood work
Thyroid levels, vitamin B12/folate, blood count, metabolic panel, and sometimes infection screens (e.g., HIV, syphilis) to exclude reversible causes. BioMed Central
APOE genotyping (select cases)
Shows genetic risk for amyloid deposition (ε4 allele) but does not diagnose disease. Used thoughtfully in memory clinics. PMC
CSF amyloid-β42 (or Aβ42/40 ratio)
Lower CSF Aβ42 (or abnormal ratio) suggests amyloid plaques in the brain. In amyloid-only (A+T–), this can be positive despite tau negativity. PMC
CSF phosphorylated tau (p-tau) and total tau
These reflect tau tangle pathology and neuronal injury. In the “without tangles” pattern, p-tau can be normal, supporting A+T– status. PMC
Plasma biomarkers (blood tests)
New blood tests (e.g., p-tau species like eMTBR-tau243) track tau and may help separate Alzheimer’s from other causes. If tau blood tests are negative while amyloid is positive, that supports an amyloid-only stage. (This field is advancing fast.) The Guardian
Pathology at autopsy (rarely, brain biopsy)
Definitive proof comes from microscopy: plaques present, tangles absent (POAD). This is mostly research, not routine. PubMed

D) Electrodiagnostic tests

Electroencephalography (EEG)
Measures brain electrical activity. Often normal or mildly slow in early cognitive disorders, but can spot seizures or patterns suggesting other diseases (e.g., Creutzfeldt-Jakob), helping rule-outs. BioMed Central
Evoked potentials (selected cases)
Visual or auditory evoked potentials can show slowed processing in sensory pathways if clinicians suspect alternative diagnoses. These are supporting tests, not Alzheimer-specific. BioMed Central

E) Imaging tests

MRI of the brain
Looks for strokes, tumors, normal-pressure hydrocephalus, or other structural causes. In amyloid-only patterns, MRI may show normal hippocampi or only mild atrophy; marked hippocampal atrophy is more typical with tau-positive Alzheimer’s. BioMed Central
Amyloid PET scan
A tracer highlights amyloid plaques. A positive amyloid PET with a negative tau PET fits an A+T– (amyloid-only) pattern. PMC
Tau PET scan
Shows tau tangles in living patients. If tau PET is negative, this supports the “without neurofibrillary tangles” picture. When both amyloid and tau PET are positive together, short-term decline risk rises. Nature
FDG-PET (metabolism PET)
Shows brain glucose metabolism. Alzheimer’s often shows temporoparietal hypometabolism, but patterns can vary; in amyloid-only stages, FDG-PET may be normal or mildly abnormal, so results must be read with the full clinical picture. BioMed Central

Non-pharmacological treatments

Diagnosis education and care-planning – Clear explanation and a written plan reduce fear, improve choices. Mechanism: lowers stress, aligns daily habits and safety.
Cognitive stimulation therapy (CST) – Group or home activities for memory/language. Mechanism: repeated use strengthens networks.
Cognitive rehabilitation – One-to-one training for personal goals (e.g., medication routine). Mechanism: compensatory strategies build independence.
Aerobic exercise (150 min/week) – Brisk walking, cycling. Mechanism: boosts blood flow, BDNF, insulin sensitivity.
Resistance training (2–3×/week) – Bands/weights. Mechanism: muscle-brain signaling, glucose control, fall prevention.
Balance and flexibility work – Tai chi, yoga. Mechanism: reduces falls, improves attention and calm.
MIND/Mediterranean-style eating – Veg, berries, nuts, olive oil, fish, whole grains. Mechanism: anti-inflammatory, vascular protection.
Sleep hygiene + OSA treatment (CPAP if needed) – Fixed sleep window, no screens late, treat apnea. Mechanism: improves amyloid clearance and daytime cognition.
Hearing aids / vision correction – Reduce cognitive load; improve safety and social life.
Social engagement – Clubs, classes, volunteering. Mechanism: cognitive reserve and mood lift.
Occupational therapy home-safety review – Labels, lighting, grab bars. Mechanism: prevents accidents, reduces confusion.
Environmental simplification – Declutter, set routines, use pillboxes and calendars. Mechanism: external memory aids.
Music therapy – Familiar music for relaxation and recall. Mechanism: taps preserved circuits and emotion.
Mindfulness and breathing exercises – 10–20 minutes daily. Mechanism: lowers stress hormones, improves attention.
Psychotherapy (CBT/supportive) – For anxiety/depression. Mechanism: better coping, fewer symptoms that mimic dementia.
Vascular risk control (non-drug parts) – Weight management, diet, exercise. Mechanism: protects small vessels and white matter.
Smoking cessation coaching – Saves vessels and oxygen delivery to brain.
Alcohol moderation – Protects sleep and executive function.
Caregiver training and support groups – Reduces burnout, improves outcomes.
Advance care planning – Power of attorney, driving plan. Mechanism: reduces crises and conflict.

Drug treatments

Important: Medication plans must be individualized by a clinician who knows the patient’s history, other drugs, kidney/liver function, and risk of side effects.

Donepezil (cholinesterase inhibitor) – 5 mg nightly ×4–6 weeks, then 10 mg nightly if tolerated. Purpose: memory/attention support. Mechanism: ↑acetylcholine. Side effects: nausea, diarrhea, vivid dreams, bradycardia.
Rivastigmine (oral or patch) (cholinesterase inhibitor) – Oral 1.5 mg bid up-titrate; Patch 4.6 mg/24h → 9.5 → 13.3. Purpose: cognition/behavior. Side effects: GI upset (less with patch), weight loss, bradycardia.
Galantamine (cholinesterase inhibitor) – ER 8 mg qAM → 16 → 24 mg. Purpose: memory/attention. Side effects: GI upset, dizziness, bradycardia.
Memantine (NMDA modulator) – 5 mg daily ↑ weekly to 10 mg bid (or XR 28 mg qAM). Purpose: behavior, attention in moderate stages; sometimes added to a cholinesterase inhibitor. Side effects: dizziness, headache, constipation.
Lecanemab (anti-Aβ mAb) – IV q2w; only for amyloid-positive, mild stage with MRI monitoring. Purpose: slow amyloid-related decline. Mechanism: clears soluble/fibrillar Aβ. Side effects: ARIA-E/H (brain swelling/bleeds), infusion reactions.
Donanemab (anti-Aβ mAb) – IV per protocol; amyloid-positive, early symptomatic disease, MRI monitoring. Purpose: slow decline. Side effects: ARIA, infusion reactions.
Aducanumab (anti-Aβ mAb; limited use/coverage) – IV per protocol; careful selection. Side effects: ARIA, headache.
Sertraline (SSRI) – 25–50 mg qAM; titrate to 100–150 mg if needed. Purpose: depression/anxiety. Mechanism: ↑serotonin. Side effects: GI upset, hyponatremia, sexual dysfunction.
Citalopram (SSRI) – 10 mg qAM → 20 mg; avoid >20 mg in older adults; get ECG if risk. Purpose: agitation/anxiety. Side effects: QT prolongation, GI upset.
Mirtazapine (NaSSA) – 7.5–15 mg qHS; helps appetite and sleep. Purpose: depression, weight loss, insomnia. Side effects: sedation, weight gain.
Trazodone (SARI) – 25–100 mg qHS. Purpose: insomnia, nighttime agitation. Side effects: sedation, orthostasis.
Melatonin (hormone) – 1–5 mg 1–2 h before bed. Purpose: circadian support. Side effects: morning grogginess in some.
Suvorexant (orexin antagonist) – 10–20 mg qHS. Purpose: insomnia with middle-of-the-night awakenings. Side effects: next-day drowsiness.
Ramelteon (melatonin agonist) – 8 mg qHS. Purpose: sleep onset. Side effects: dizziness, fatigue.
Quetiapine (atypical antipsychotic; short-term only if severe distress/risk) – 12.5–25 mg qHS; lowest effective dose. Purpose: severe agitation/psychosis. Risks: stroke, mortality warning, sedation, orthostasis.
Risperidone (atypical antipsychotic; short-term, lowest dose) – 0.25–0.5 mg qHS. Risks: extrapyramidal symptoms, stroke/mortality warning.
Dextromethorphan-quinidine – Per label. Purpose: agitation in some patients. Side effects: dizziness, falls, QT effects, drug interactions.
Levetiracetam (anti-seizure) – 250–500 mg bid if seizures. Purpose: seizure control; low interaction profile. Side effects: irritability in some.
Buspirone (anxiolytic) – 5 mg bid → 10 mg tid. Purpose: anxiety without sedation. Side effects: dizziness, nausea.
Prazosin (α1-blocker) – 1 mg qHS → 2–4 mg. Purpose: nightmares or severe nighttime agitation in select cases. Side effects: low BP, dizziness.

Notes on anti-amyloid mAbs (lecanemab/donanemab/aducanumab): require confirmed amyloid positivity, careful selection, MRI monitoring, and discussion of ARIA risk, especially if there are many microbleeds or if the patient needs blood thinners. These are not for everyone and are used in early symptomatic stages.

Dietary molecular supplements

Evidence for supplements is mixed. Discuss with your clinician, especially if you take blood thinners or have kidney/liver issues.

Omega-3 (DHA/EPA) – 1–2 g/day combined. Function: anti-inflammatory, vascular support. Mechanism: membrane fluidity, resolvins.
Vitamin D3 – 1000–2000 IU/day (adjust to level). Function: immune and brain health. Mechanism: nuclear receptor signaling.
B-complex (B12, B6, folate) – B12 1000 mcg/day (or as needed), B6 25–50 mg/day, folate 400–800 mcg/day. Function: lower homocysteine, support myelin.
Magnesium L-threonate – Up to ~2 g/day (elemental Mg lower); follow label. Function: sleep, calm, synaptic plasticity (theoretical).
Curcumin (enhanced bioavailability) – 500–1000 mg/day. Function: antioxidant; Mechanism: NF-κB modulation; may interact with blood thinners.
Resveratrol – 100–200 mg/day. Function: antioxidant; Mechanism: sirtuin pathways; evidence mixed.
EGCG (green tea extract) – 200–400 mg/day standardized. Function: antioxidant; Mechanism: reduces oxidative stress; caution liver in high doses.
Phosphatidylserine – 100 mg tid. Function: membrane support; small symptomatic benefit in some.
Coenzyme Q10 (ubiquinone/ubiquinol) – 100–200 mg/day. Function: mitochondrial support.
Probiotic with prebiotic fiber – Per label. Function: gut-brain axis, inflammation modulation.

Immunity booster / regenerative / stem-cell” drugs

None of these are standard approved treatments for Alzheimer’s. They are experimental or under study. Consider only in clinical trials.

Sargramostim (GM-CSF) – Dose only per trial. Function: immune modulation; Mechanism: activates innate immunity that might affect amyloid clearance.
G-CSF (filgrastim) – Trial-based. Function: mobilizes stem cells; experimental neuroprotection signals in models.
Intranasal insulin – Trial-based dosing. Function: improves brain insulin signaling. Mechanism: glucose use and synaptic support.
NGF/BDNF gene or cell-based approaches – Research only. Function: trophic support for neurons.
Mesenchymal stem cell infusions – Trial-based. Function: paracrine anti-inflammatory effects; not proven for routine care.
Nicotinamide riboside / NAD+ targeted pharmacologics – Border of supplement/drug; Function: mitochondrial support; Mechanism: sirtuin/NAD+ pathways; still investigational for cognition.

Surgeries

There is no curative surgery for Alzheimer biology. These procedures address co-problems or are experimental.

Cochlear implant for severe hearing loss – Why: restoring hearing reduces cognitive load, social isolation, and depression.
Cataract surgery – Why: clearer vision improves safety, reading, navigation.
Ventriculoperitoneal shunt (for true normal-pressure hydrocephalus, not AD) – Why: treats gait/cognition issues due to NPH; helps when NPH is the real cause.
Deep brain stimulation (DBS; research) – Why: experimental modulation of memory circuits.
Vagus nerve stimulation implant (research) – Why: experimental neuromodulation for attention/arousal.

Prevention tips

Move daily – Aim 150 minutes/week + strength work.
Eat MIND-style – Plants, berries, nuts, fish, olive oil, whole grains.
Sleep 7–8 hours – Screen for apnea if you snore or stop breathing.
Treat hearing loss – Hearing aids are brain aids.
Control blood pressure, sugar, and cholesterol – Protects brain vessels.
Don’t smoke – Brain and vessel health improve quickly after quitting.
Limit alcohol – Keep it light or none.
Stay socially and mentally active – Clubs, classes, games, new learning.
Manage stress, anxiety, and depression – Seek help early.
Avoid strong anticholinergic drugs when possible – Ask your doctor about safer options.

When to see a doctor (red flags)

Memory or thinking changes that affect work, money, driving, or safety.
Getting lost in familiar places.
New depression, anxiety, or personality change that does not lift.
Falls, fainting, or spells that could be seizures.
Daytime sleepiness or loud snoring with pauses in breathing.
Sudden changes (think strokes) or severe headaches.
Any time family members feel something is wrong.

What to eat and what to avoid

Eat mostly: colorful vegetables, leafy greens, berries, citrus, apples, beans, lentils, whole grains, nuts (walnut, almond), seeds, olive oil, fish (especially fatty fish like salmon/sardines), yogurt or fermented foods, herbs/spices (turmeric, rosemary), and plenty of water. These foods support blood vessels, lower inflammation, and feed the gut microbiome that talks to your brain.

Limit or avoid: ultra-processed foods, sugary drinks, refined white flour snacks, deep-fried fast food, trans fats, excess salt, heavy alcohol, and big late-night meals that wreck sleep. Be cautious with grapefruit if you take certain meds, and ginkgo/garlic/fish-oil at high doses if you are on blood thinners (ask your doctor).

FAQs

1) Is “Alzheimer’s without tangles” real?
Yes, but it’s uncommon and complex. It usually means amyloid is present while tau tangles are not detected with current tests.

2) Does no tau mean no symptoms?
Not always. Some people have mild symptoms from amyloid and other factors (sleep, mood, hearing, blood vessels).

3) Can it turn into typical Alzheimer’s with tangles later?
Sometimes. Some A+T− people convert to A+T+ over time, but not all do.

4) How is it confirmed?
By clinical exam, MRI, labs, and biomarkers: amyloid PET or CSF Aβ (positive), tau PET or CSF p-tau (negative/normal).

5) Are anti-amyloid drugs an option?
Maybe—only if amyloid is confirmed, the stage is early symptomatic, and the patient accepts MRI monitoring and ARIA risk.

6) Do cholinesterase inhibitors help if there are no tangles?
They can support symptoms (attention, daily function) in some patients, regardless of tau status.

7) What if sleep apnea is present?
Treating apnea often improves thinking, mood, and energy.

8) Can depression or anxiety look like dementia?
Yes. Treating them can sharpen thinking and improve quality of life.

9) Do hearing aids really matter?
Yes. Better hearing reduces cognitive load and isolation.

10) Is heavy alcohol a problem?
Yes. It damages brain tissue and disrupts sleep.

11) What diet is best?
MIND or Mediterranean-style eating has the strongest brain support data.

12) Are supplements required?
Not required. Some may help specific gaps (e.g., vitamin D, B12). Evidence for many supplements is mixed.

13) Is there surgery to cure it?
No. Surgeries help co-problems (hearing, vision, NPH). Research neuromodulation exists but is not standard.

14) How often should we follow up?
Commonly every 6–12 months, sooner if symptoms change or new treatments start.

15) What about driving?
Discuss early. Use road tests and family input. Safety first, revisit as disease or symptoms change.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.